興齊眼藥(300573.SZ)加替沙星眼用凝膠新納入及小牛血去蛋白提取物眼用凝膠退出國家醫保目錄
格隆匯8月21日丨興齊眼藥(300573.SZ)公佈,近日,根據國家醫療保障局、人力資源社會保障部下發的《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄〉的通知》【醫保發[2019]46號】,公司產品加替沙星眼用凝膠新納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2019年版)》(“國家醫保目錄”)。此次公司新納入的產品屬於醫保乙類品種,眼用凝膠劑型。
此外,公司的小牛血去蛋白提取物眼用凝膠退出國家醫保目錄。原藥品分類及編號為其他眼科用藥-1223,屬於醫保乙類品種。
此次發佈的國家醫保目錄自2020年1月1日起實施,此次公司產品新納入和退出國家醫保目錄對公司經營業績的影響暫時無法估計,短期內不會對公司的業績產生重大影響,敬請投資者理性投資,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.